Liyan Miao

2.9k total citations
129 papers, 2.0k citations indexed

About

Liyan Miao is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Liyan Miao has authored 129 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Molecular Biology, 20 papers in Pharmacology and 19 papers in Oncology. Recurrent topics in Liyan Miao's work include Pharmacogenetics and Drug Metabolism (15 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Liyan Miao is often cited by papers focused on Pharmacogenetics and Drug Metabolism (15 papers), Chronic Lymphocytic Leukemia Research (9 papers) and Lung Cancer Treatments and Mutations (9 papers). Liyan Miao collaborates with scholars based in China, United States and Spain. Liyan Miao's co-authors include Chenrong Huang, John H. Zhang, Zhenya Shen, Jian Yang, Sheng Ma, John W. Calvert, Ling Xue, Linsheng Liu, Jiping Tang and Yun Dai and has published in prestigious journals such as SHILAP Revista de lepidopterología, Stroke and Journal of Hazardous Materials.

In The Last Decade

Liyan Miao

114 papers receiving 1.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liyan Miao China 25 547 317 307 229 185 129 2.0k
Yuji Kumagai Japan 25 493 0.9× 254 0.8× 190 0.6× 412 1.8× 230 1.2× 127 2.0k
Eman Said Egypt 23 562 1.0× 199 0.6× 188 0.6× 324 1.4× 70 0.4× 71 1.4k
Thomas Kerbusch Netherlands 22 411 0.8× 359 1.1× 239 0.8× 347 1.5× 134 0.7× 47 1.9k
Itsuko Ishii Japan 22 644 1.2× 379 1.2× 193 0.6× 194 0.8× 84 0.5× 114 1.9k
Keiko Hosohata Japan 24 685 1.3× 148 0.5× 217 0.7× 180 0.8× 143 0.8× 98 1.8k
Bart A. Ploeger Netherlands 26 630 1.2× 498 1.6× 230 0.7× 364 1.6× 169 0.9× 67 2.3k
Yuxia Zhao China 27 1.0k 1.9× 216 0.7× 174 0.6× 180 0.8× 472 2.6× 67 2.3k
Pei Hu China 26 778 1.4× 392 1.2× 271 0.9× 589 2.6× 157 0.8× 222 2.6k
Lu Shen China 24 976 1.8× 386 1.2× 102 0.3× 355 1.6× 186 1.0× 106 2.3k
Shiro Ueda Japan 25 871 1.6× 354 1.1× 210 0.7× 157 0.7× 169 0.9× 111 2.7k

Countries citing papers authored by Liyan Miao

Since Specialization
Citations

This map shows the geographic impact of Liyan Miao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liyan Miao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liyan Miao more than expected).

Fields of papers citing papers by Liyan Miao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liyan Miao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liyan Miao. The network helps show where Liyan Miao may publish in the future.

Co-authorship network of co-authors of Liyan Miao

This figure shows the co-authorship network connecting the top 25 collaborators of Liyan Miao. A scholar is included among the top collaborators of Liyan Miao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liyan Miao. Liyan Miao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Yaoqi, Yitian Chen, Yongan Tang, et al.. (2025). Breaking the barriers in effective and safe Toll-like receptor stimulation via nano-immunomodulators for potent cancer immunotherapy. Journal of Controlled Release. 382. 113667–113667. 1 indexed citations
2.
Fang, Xinyi, Liyan Miao, Yanjiao Zhang, et al.. (2025). Traditional Chinese medicine phenomics research on glycolipid metabolism disorder: a review. Digital Chinese Medicine. 8(1). 49–58. 1 indexed citations
3.
Qin, Yi, et al.. (2025). Development and validation of a UPLC-MS/MS method for almonertinib with its active metabolite HAS-719 and anlotinib in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 260. 116766–116766. 1 indexed citations
4.
Zhang, Hua, et al.. (2024). Clinical pharmacokinetic characteristics of Jaktinib in subjects with hepatic impairment in a phase I trial. Drug Metabolism and Pharmacokinetics. 59. 101030–101030. 1 indexed citations
5.
Xue, Ling, et al.. (2024). Dynamics and implications of anti-drug antibodies against adalimumab using ultra-sensitive and highly drug-tolerant assays. Frontiers in Immunology. 15. 1429544–1429544. 1 indexed citations
6.
7.
Zheng, Meng, Qingfeng Liu, Hua Zhang, et al.. (2024). Development of a Specifically Labeled 89Zr Antibody for the Noninvasive Imaging of Tumors Overexpressing B7-H3. Molecular Pharmaceutics. 21(10). 5205–5216. 2 indexed citations
8.
9.
10.
Xue, Ling, Linsheng Liu, Yun Li, et al.. (2024). Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease. Frontiers in Pharmacology. 15. 1430120–1430120. 1 indexed citations
11.
Li, Yun, et al.. (2024). What are the benefits of therapeutic drug monitoring in the optimization of adalimumab therapy? a systematic review and meta-analysis up to 2022. Frontiers in Pharmacology. 15. 1376708–1376708. 1 indexed citations
12.
Song, Zaiwei, Dan Jiang, Daobin Zhou, et al.. (2024). Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors (2024). Chinese Journal of Cancer Research. 36(2). 240–256. 3 indexed citations
13.
Bian, Yicong, Sheng Ma, Wei Chen, et al.. (2023). Pharmacokinetics, Mass Balance and Metabolism of [14C]HSK21542, a Novel Kappa Opioid Receptor Agonist, in Humans. European Journal of Drug Metabolism and Pharmacokinetics. 48(6). 723–731. 4 indexed citations
14.
Chen, Xionghui, Xuying He, Feng Xu, et al.. (2023). Fractalkine Enhances Hematoma Resolution and Improves Neurological Function via CX3CR1/AMPK/PPARγ Pathway After GMH. Stroke. 54(9). 2420–2433. 19 indexed citations
15.
Chen, Jingjing, Liang Huang, Linan Zeng, et al.. (2023). The reference range of lamotrigine in the treatment of epilepsy in children: a systematic review. European Journal of Clinical Pharmacology. 80(1). 1–10. 3 indexed citations
16.
Chen, Zhiyao, et al.. (2019). Comprehensive Evaluation of the Factors Affecting Plasma Circulating Cell-Free DNA Levels and Their Application in Diagnosing Nonsmall Cell Lung Cancer. Genetic Testing and Molecular Biomarkers. 23(4). 270–276. 3 indexed citations
17.
Zhang, Jun, et al.. (2011). Mutation-Sensitive Molecular Switch Method to Detect CES1A2 Mutation in the Chinese Han and Yao Populations. Genetic Testing and Molecular Biomarkers. 15(9). 659–662. 7 indexed citations
18.
Miao, Liyan. (2011). Determination of Five Coumarin Components in Duliang Capsules by HPLC. Chinese Journal of Pharmaceuticals. 1 indexed citations
19.
Xie, Cheng, et al.. (2009). Analysis of elimination in high dose methotrexate therapy in children acute lymphoblastic leukemia. Chinese Journal of Hospital Pharmacy. 29(5). 398–400. 1 indexed citations
20.
Miao, Liyan, et al.. (2007). Effects of different diet on pharmacokinetics of calcium dobesilate in healthy volunteers. Chinese Journal of New Drugs and Clinical Remedies. 26(3). 196–199.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yuji Kumagai Breakdown of academic impact, for papers by Eman Said Breakdown of academic impact, for papers by Thomas Kerbusch Breakdown of academic impact, for papers by Itsuko Ishii Breakdown of academic impact, for papers by Keiko Hosohata Breakdown of academic impact, for papers by Bart A. Ploeger Breakdown of academic impact, for papers by Yuxia Zhao Breakdown of academic impact, for papers by Pei Hu Breakdown of academic impact, for papers by Lu Shen Breakdown of academic impact, for papers by Shiro Ueda
Rankless by CCL
2026